Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.50 |
| ▸ | SMPD2 | O60906 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 4/20 | 0.41 |
| ▸ | PPARA | Q07869 | 4/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173510 | 1.00 | SIGMAR1 (0.50) | SIGMAR1SMPD2SLC6A2SLC6A4NR4A1 | |
| SCHEMBL7366363 | 1.00 | SIGMAR1 (0.50) | SIGMAR1SMPD2SLC6A2SLC6A4NR4A1 | |
| SCHEMBL29643326 | 1.00 | SIGMAR1 (0.50) | SIGMAR1SMPD2SLC6A2SLC6A4NR4A1 | |
| SCHEMBL29643341 | 1.00 | SIGMAR1 (0.50) | SIGMAR1SMPD2SLC6A2SLC6A4NR4A1 | |
| SCHEMBL8803002 | 0.85 | SIGMAR1 (0.49) | SIGMAR1SMPD2SLC6A2SLC6A4NCEH1 | |
| SCHEMBL7563347 | 0.83 | SMPD2 (0.49) | SIGMAR1SMPD2SLC6A2SLC6A4NR4A1 | |
| SCHEMBL29643295 | 0.83 | SIGMAR1 (0.50) | SIGMAR1SLC6A2SLC6A4NCEH1 | |
| SCHEMBL4082840 | 0.82 | SMPD2 (0.48) | SIGMAR1SMPD2NR4A1NR4A2NR4A3 | |
| SCHEMBL1697074 | 0.82 | SMPD2 (0.48) | SIGMAR1SMPD2NR4A1NR4A2NR4A3 | |
| Leucine SCHEMBL28593704 | 0.82 | SLC7A5 (0.40) | SIGMAR1SMPD2SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1578 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085582-A1 | PROTEIN CAGES | THE UNIVERSITY OF SYDNEY (AU) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731266-A1 | NANOPARTICLE COMPOSITIONS ASSOCIATED WITH PEPTIDES | The Regents of the University of Michigan (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-12605425-B2 | TNF muteins and uses thereof | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2026-04-21 | — | — | US | disclosed |
| EP-4710935-A2 | NOVEL IMMUNOTHERAPEUTIC COMPOSITION AND USES THEREOF | Aravax Pty Ltd (AU) | 2026-03-18 | — | — | EP | disclosed |
| EP-3980085-B1 | COMPOSITIONS AND METHODS OF USING SAME FOR TISSUE REGENERATION | UNIV RAMOT (IL) | 2026-03-11 | — | — | EP | disclosed |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260049121-A1 | SUPRAMOLECULAR HIGH AFFINITY PROTEIN-BINDING SYSTEM FOR PURIFICATION OF BIOMACROMOLECULES | UNIV JOHNS HOPKINS (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | CIDARA THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12466875-B2 | Supramolecular high affinity protein-binding system for purification of biomacromolecules | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-11-11 | — | — | US | disclosed |
| WO-1997035971-A1 | A NOVEL MAMMALIAN GENE, bcl-w, BELONGS TO THE bcl-2 FAMILY OF APOPTOSIS-CONTROLLING GENES | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-10-02 | — | — | WO | disclosed |
| WO-1997035887-A1 | PRECURSORS OF CATALYTIC ANTIBODIES | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-10-02 | — | — | WO | disclosed |
| WO-1997033614-A1 | USE OF COXIELLA BACTERIA TO TREAT AUTOIMMUNE DISEASE | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1997-09-18 | — | — | WO | disclosed |
| WO-1997025344-A1 | CLIP ANALOGUES AND AUTOIMMUNE DISEASE | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 1997-07-17 | — | — | WO | disclosed |
| WO-1997023629-A1 | A NOVEL RECEPTOR-TYPE TYROSINE KINASE AND USE THEREOF | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-07-03 | — | — | WO | disclosed |
| WO-1997023501-A1 | THERAPEUTIC COMPOSITIONS | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-07-03 | — | — | WO | disclosed |
| WO-1997021727-A1 | MYCOPLASMA RECOMBINANT POLYPEPTIDE VACCINES | THE UNIVERSITY OF MELBOURNE (AU) | 1997-06-19 | — | — | WO | disclosed |
| WO-1997015663-A1 | A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-05-01 | — | — | WO | disclosed |
| WO-1997012037-A1 | A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-04-03 | — | — | WO | disclosed |
| WO-1997004091-A1 | NOVEL RECEPTOR LIGANDS AND GENETIC SEQUENCES ENCODING SAME | AMRAD OPERATIONS PTY. LTD. (AU) | 1997-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605425-B2 | TNF muteins and uses thereof | TNFRSF1A, TNF, TNFSF11 | SIGMAR1 1364/4885SMPD2 2716/4885SLC6A2 541/4885 |
| US-20260049121-A1 | SUPRAMOLECULAR HIGH AFFINITY PROTEIN-BINDING SYSTEM FOR PURIFICATION OF BIOMACROMOLECULES | IL33, MAX, HM13 | SIGMAR1 3563/4885SMPD2 3787/4885SLC6A2 4482/4885 |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | SIGMAR1 3294/4885SMPD2 675/4885SLC6A2 680/4885 |
| US-12569565-B2 | Compositions and methods for the treatment of viral infections | ALB, FCGR3B, FCGR1A | SIGMAR1 2289/4885SMPD2 998/4885SLC6A2 971/4885 |
| US-20260000781-A1 | FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF | FCGR2A, FCGR1A, FCGR3B | SIGMAR1 2401/4885SMPD2 453/4885SLC6A2 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.